VGF and Its Derived Peptides in Amyotrophic Lateral Sclerosis

Area of Science:

• Neuroscience
• Biochemistry
• Biomarker Discovery

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no effective treatments.
• Delayed diagnosis, caused by a lack of early biomarkers, hinders therapeutic strategy development.
• Current neurotransmitter biomarkers are not reliably detectable in body fluids for ALS diagnosis.

Purpose of the Study:

• To explore the potential of proVGF-derived peptides as early diagnostic biomarkers for ALS.
• To review alterations of VGF peptides in the spinal cord and body fluids of ALS patients.
• To identify limitations in current research and guide future investigations.

Main Methods:

• Literature review focusing on proVGF peptides and their role in ALS.
• Analysis of studies using mass spectrometry and biochemical assays for neuropeptide detection.
• Examination of VGF peptide expression in nervous tissue and bodily fluids.

Main Results:

• ProVGF peptides are expressed in the nervous and endocrine systems and are found in blood, urine, and cerebrospinal fluid.
• Alterations in VGF peptide levels are observed in the spinal cord and body fluids in ALS.
• These peptides show promise as potential biomarkers for ALS diagnosis.

Conclusions:

• ProVGF-derived peptides represent a promising avenue for developing early diagnostic biomarkers for ALS.
• Further research is needed to overcome limitations in current investigations and validate these peptides.
• Identifying reliable biomarkers is crucial for advancing therapeutic strategies against ALS.